Comment on 'A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension' by Lin et al

Harald Mischak^{1

2}

Affiliations

Comment

Harald Mischak. J Hypertens. 2023.

. 2023 Oct 1;41(10):1666.

doi: 10.1097/HJH.0000000000003489.

Harald Mischak^{1

2}

No abstract available

Comment on

A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension.
Lin L, Wang C, Ren J, Mei M, Zheng L, Yang J. Lin L, et al. J Hypertens. 2023 Aug 1;41(8):1306-1312. doi: 10.1097/HJH.0000000000003467. Epub 2023 May 19. J Hypertens. 2023. Retraction in: J Hypertens. 2023 Oct 1;41(10):1673. doi: 10.1097/HJH.0000000000003551. PMID: 37199562 Free PMC article. Retracted.

1. Lin L, Wan C, Ren J, Mei M, Zheng L, Yang J. A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension. J Hypertens 2023; 41:1306–1312. [Retracted].
1. Good DM, Zürbig P, Argiles A, Bauer HW, Behrens G, Coon JJ, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010; 9:2424–2437.
1. Mischak H, Vlahou A, Ioannidis JP. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem 2013; 46:432–443.
1. Mavrogeorgis E, Mischak H, Latosinska A, Siwy J, Jankowski V, Jankowski J. Reproducibility evaluation of urinary peptide detection using CE-MS. Molecules 2021; 26:7260.
1. Latosinska A, Siwy J, Mischak H, Frantzi M. Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: the past, the present, and the future. Electrophoresis 2019; 40:2294–2308.